NCT02597036 2025-10-23A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid TumorsEli Lilly and CompanyPhase 1 Terminated62 enrolled 25 charts
NCT01369433 2020-09-01A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsAVEO Pharmaceuticals, Inc.Phase NA Terminated225 enrolled 7 charts
NCT01862328 2020-06-22Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsTakedaPhase 1 Completed64 enrolled 21 charts